Aurealis Therapeutics launches Venous Leg Ulcer (VLU) scientific expert group, an important step towards AUP-16 VLU phase 2 clinical trial
Aurealis Therapeutics, a Swiss-Finnish clinical-stage synthetic biology company developing bacteria-based multi-target cell and gene therapies for chronic wounds and cancer, announces the initiation of its Venous Leg Ulcer (VLU) scientific expert group. This initiative is an important step towards the planning and execution of the Phase 2 clinical trial of AUP-16 for Venous Leg Ulcers […]
